# Evaluate the Safety of Linaclotide in IBS-C Patients in China

> **NCT04462900** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 3028 (actual)

## Conditions studied

- Irritable Bowel Syndrome-IBS

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04462900
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-18
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 3028 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462900, "Evaluate the Safety of Linaclotide in IBS-C Patients in China". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT04462900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*